| Literature DB >> 24506826 |
William Rainey Johnson, David Fedor, Sunil Singhal1.
Abstract
This compares outcome measures of current pectus excavatum (PEx) treatments, namely the Nuss and Ravitch procedures, in pediatric and adult patients. Original investigations that stratified PEx patients based on current treatment and age (pediatric=0-21; adult 17-99) were considered for inclusion. Outcome measures were: operation duration, analgesia duration, blood loss, length of stay (LOS), outcome ratings, complications, and percentage requiring reoperations. Adult implant patients (18.8%) had higher reoperation rates than adult Nuss or Ravitch patients (5.3% and 3.3% respectively). Adult Nuss patients had longer LOS (7.3 days), more strut/bar displacement (6.1%), and more epidural analgesia (3 days) than adult Ravitch patients (2.9 days, 0%, 0 days). Excluding pectus bar and strut displacements, pediatric and adult Nuss patients tended to have higher complication rates (pediatric - 38%; adult - 21%) compared to pediatric and adult Ravitch patients (12.5%; 8%). Pediatric Ravitch patients clearly had more strut displacements than adult Ravitch patients (0% and 6.4% respectively). These results suggest significantly better results in common PEx surgical repair techniques (i.e. Nuss and Ravitch) than uncommon techniques (i.e. Implants and Robicsek). The results suggest slightly better outcomes in pediatric Nuss procedure patients as compared with all other groups. We recommend that symptomatic pediatric patients with uncomplicated PEx receive the Nuss procedure. We suggest that adult patients receive the Nuss or Ravitch procedure, even though the long-term complication rates of the adult Nuss procedure require more investigation.Entities:
Mesh:
Year: 2014 PMID: 24506826 PMCID: PMC3922335 DOI: 10.1186/1749-8090-9-25
Source DB: PubMed Journal: J Cardiothorac Surg ISSN: 1749-8090 Impact factor: 1.637
Figure 1This shows the selection and filtration process.
This is a comprehensive list of all the studies that included the Nuss procedure
| | | | | | | | | |||||||||
| | | | | | ||||||||||||
| | | | | |||||||||||||
| | | | | | | | | |||||||||
| | | | | | | | | |||||||||
| | | | | |||||||||||||
| | | | | | | |||||||||||
| | | | ||||||||||||||
| Zganjer [ | 128 | R | 3.6 | 13.8 (8–21) | | --/4 | 35 | 10 | 95/73d | 41/20 | 4.7 | 4.7 | 42 | Better | | Better |
| Esteves [ | 26 | R | | 15.3 (5.0-19) | 90.3 | 3/-- | | 5.07 | | 4/-- | | | 12 | | | |
| Nuri [ | 12 | R | 3.6 (0.3 - 7) | 9 (4.0-21) | | | | | | | 0 | 33.3 | | | | |
| Densmore [ | 117 | R | 4 | 12.9 (8.0-18) | 118 | --/3.8 | <10 | 5.8 | | 21/-- | 16 | 12 | 100 | | | |
| Mao [ | 115 | R | | 7.9 (2.7-18) | 59.5 | --/5.1 | | 8.5 | 98/90 | 20/6 | 1.7 | 2.6 | 32 | | | |
| Felts [ | 25 | | 2.2 | 13.8 (5.0-18) | | 3/-- | | 7 | 96/-- | 20/-- | 4 | 4 | 52 | | Better | |
| Lam [ | 19 | R | | 15.4 (13–18) | 72.1 | 3.7/-- | | 4.5 | | | | | | | | |
| Sigalet [ | 26 | P | >2 | 13.2 | | | | 5 | | | 11.5 | 11.5 | | Better | Better | Same |
| Kubiak [ | 15 | | | 15.9 (10.7-18.1) | | | | | | 33/20 | 6.7 | 13.3 | | | Better | Better |
| Kelly [ | 284 | P | 0.2 | 13.6 (8.0-21) | | | | | 97/90 | 98/47 | | 2.5 | | | | |
| Coln [ | 123 | R | <2 | 13 (5.0-18) | | --/2.9 | | 3.1 | | 11/-- | | 0.8 | | Better | | Better |
| Aronson [ | 141 | | | 13 (5.0-17) | 65c | | | 7c | | 24/-- | 0.7 | 12.8 | 55 | | | |
| Kim [ | 39 | R | 3.4 | 8.9 (1.5-19) | 60.7 | | | 5.9 | 83/-- | 25/-- | 7.7 | 5.1 | | | | |
| Bohosiewicz [ | 66 | R | | 11.8 (1.0-19) | | | | | --/85 | 15/-- | 1.5 | | 36 | | | |
| Watanabe [ | 53 | R | | 9 (4.0-18) | 76 | --/4.3 | 4 | 8.9 | | 26/2 | 3.8 | 7.5 | | | | |
| Ohno [ | 23 | R | | 7.6 (3.0-19) | 143.5 | | 16.5 | 7.9 | --/78 | 13/-- | | 8.7 | | | | |
| Inge [ | 43 | R | 1.4 (0.6 - 2.8) | 11 (4–19) | 70 | 0/-- | | 2.4 | 90/ | 14/-- | 4.7 | 4.7 | | | | |
| Fonkalsrud [ | 68 | R | | 12 (5.0-19) | 75 | 3/5 | 90 | 6.5 | | 13/-- | 10.2 | 8.8 | 26 | | | |
| Molik [ | 35 | R | | 9.5 (5.0-20) | 198 | 3/3.8 | | 4.8 | | 37/-- | 22.9 | 17.1 | | | | |
| Miller [ | 80 | R | | 9.4 (<21) | 53 | | 20 | 3.7 | 95/-- | 45/8 | 5 | 5 | 20 | Better | | |
| Engum [ | 20 | R | 1.2 (0.2-1.6) | 8.2 (5–15) | | | | 4.9 | | 40/35 | 15 | 20 | | | | |
| Nuss [ | 42 | R | 4.6 (1–9.2) | (<15) | 15 | 4.3 | 87/73d | 24/7 | 4.8 | 4.8 |
The table is divided horizontally with bold & plain text to differentiate between pediatric and adult patients. Within each subgroup studies are organized in reverse chronological order from top to bottom based on publication date.
a= >3% patients reported to have Marfans.
b = >20% of patients reported to have scoliosis.
c = Median (not included in weighted averages).
d = specified as long-term outcomes.
P/R = Prospective/Retrospective Cohort Study.
This is a comprehensive list of all the studies that included the Ravitch procedure
| | | | | | | | | | | |||||||
| | | | | | ||||||||||||
| | | | | | | | | | | | ||||||
| Lam [ | 24 | | | 15.5 (13–18) | 84.1 | 1.3/2.8 | | 3.9 | | | | 50 | | | | |
| Hu [ | 398 | R | 4.2 (1–16) | 4.6 (2.5-18) | | | | | 99/-- | 1.3/-- | 7 | 1 | | Better | Better | Better |
| Kelly [ | 43 | P | 0.2 | 15.9 (8.0-21) | | | | | 98/68 | 63/42 | | | | Better | | |
| Inge [ | 25 | R | 3.5 (2.5-4) | 12 (4–18) | 195 | 0/-- | 197 | 4.4 | 85/-- | 4/-- | 0 | 0 | | | | |
| Lansman [ | 75 | R | 0.5-13 | 8.2 (<16) | 121 | | | | | 41/-- | 17 | 17.3 | | | | |
| Molik [ | 68 | R | | 12.6 (5.0-20) | 282 | 0.6/1.8 | | 4 | | 19.1/-- | 6 | 0 | | | | |
| Miller [ | 32 | R | | 11.5 (0–21) | 143 | | 200 | 3.2 | 94/-- | 18.8/-- | 3 | | | Better | | |
| Lane-Smith [ | 161 | R | 8.8 (1–21.5) | 6.4 (2–17) | 150 | | 80 | 6.1c | 83/-- | | 7 | | | | | |
| Haller [ | 352 | R | >2 | (1–17) | | | | | 99/78 | | <1 | | | | | |
| Gilbert [ | 32 | R | 2.2 | (3–16) | | | | | | 3.1/3.1 | 0 | 34 | 100 | | | |
| Holcomb [ | 40 | R | 3.8 | (2–16) | 95/68 | 5 |
The table is divided horizontally with bold and plain text to differentiate between pediatric and adult patients. Within each subgroup studies are organized in reverse chronological order from top to bottom based on publication date.
a = >3% patients reported to have marfans.
b = >20% of patients reported to have scoliosis.
c = decreased to 4.8 after 1986.
d = occurred before minimal cartilage resection.
P/R = Prospective/Retrospective Cohort Study.
This is a comprehensive list of all the studies that included Robicsek and Implant procedures
| | | | | | | | | | ||||||||
| | | | | | | | | | | |||||||
| | | | | | | | | | ||||||||
| Luzzi [ | 23 | R | | 16 | | | | 5 | 89/64 | 47.8/-- | 9 | | | Better | No change | |
| Lansman [ | 8 | R | (0.5-13) | <16 | 87 | 0/-- | 88/38 | 12.5/-- | 0 | 12.5 |
The table is divided horizontally with bold and plain text to differentiate between pediatric Robicsek and adult surgical implant patients. Within each subgroup studies are organized in reverse chronological order from top to bottom based on publication date.
P/R = Prospective/Retrospective Cohort Study.
This displays the weighted averages based on cohort size for each of our subgroups
| 2 | 13 | 22 | ||||
| | 3.9 (0.2 - 21.5) (n = 1096) | 2.1 (0.2-7) (n = 859) | ||||
| | 7.2 (0–21) (n = 809) | 12.0 (1.5-21, n = 1458) | ||||
| 87 (n = 8) | 166 (84–282, n = 385) | 86 (65–198, n = 618) | ||||
| | 0 (n = 8)/ | 0.6 (0–1.3, n = 117)/2.1 (1.8-20, n = 92) | 2.5 (0–3, n = 216)/4.1 (3–5.1, n = 639) | |||
| | | | 111 (80–200, n = 218) | 28.6 (4–90, n = 511) | ||
| 5 (n = 23) | 5 (3.2-6.1, n = 310) | 6.1 (3.1-10, n = 982) | ||||
| 89 (88–89, n = 31)/54 (38–64, n = 31) | 96 (83–99, n = 1051)/76 (68–78, n = 435) | 95 (83–97, n = 756)/85 (73–90, n = 658) | ||||
| 36 (12.5-47.8, n = 31)/ | 12.5 (1.3-63, n = 673)/25 (3.1-42, n = 75) | 38 (4–98, n = 1443)/25 (2–47, n = 737) | ||||
| 6.3 (0–9, n = 31) | 5.3 (0–17, n = 1183) | 6.3 (0–23, n = 1025) | ||||
| | 12.5 (n = 8) | 6.4 (0–50, n = 622) | 6.6 (0.8-33.3, n = 1389) | |||
| | | | 100 (n = 32) | 47 (n = 766) | ||
| | Better (n = 23) | Better (n = 473) | Better (n = 357) | |||
| | No change (n = 23) | Better (n = 398) | Better (n = 66) | |||
| Better (n = 398) | Better (n = 292) |
The table is divided vertically with bold and plain text to differentiate between pediatric and adult patients.